middle.news
Orthocell’s US Remplir Sales Reach $300K as Cash Reserves Hit $48M
9:30am on Monday 20th of April, 2026 AEST
•
Healthcare
Read Story
Orthocell’s US Remplir Sales Reach $300K as Cash Reserves Hit $48M
9:30am on Monday 20th of April, 2026 AEST
Key Points
Q1 revenue steady at $3.2 million with US sales reaching $300k
Year-to-date revenue up 45% to $9.4 million versus prior year
Remplir gains traction in US hospitals and military medical centres
Strong cash reserves of AU$48 million provide 4.6-year runway
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Orthocell (ASX:OCC)
OPEN ARTICLE